ABSTRACT
Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Aldo L. Schenone, MD
- A. Michael Lincoff, MD⇑
- Department of Cardiovascular Medicine; Heart, Vascular, and Thoracic Institute; Director, C5Research (Cleveland Clinic Coordinating Center for Clinical Research); Director, Center for Clinical Research, Lerner Research Institute, Cleveland Clinic; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
- Address:
A. Michael Lincoff, MD, Department of Cardiovascular Medicine, J2-3, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; lincofa{at}ccf.org
ABSTRACT
Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.